↓ Skip to main content

Dove Medical Press

Article Metrics

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

Overview of attention for article published in Neuropsychiatric Disease and Treatment, October 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter
6 tweeters
facebook
1 Facebook page

Readers on

mendeley
12 Mendeley
Title
Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
Published in
Neuropsychiatric Disease and Treatment, October 2018
DOI 10.2147/ndt.s176676
Pubmed ID
Authors

Taro Kishi, Kazuto Oya, Yuki Matsui, Ikuo Nomura, Kenji Sakuma, Makoto Okuya, Yuki Matsuda, Kiyoshi Fujita, Toshihiko Funahashi, Reiji Yoshimura, Nakao Iwata

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 2 17%
Student > Master 2 17%
Student > Doctoral Student 2 17%
Student > Ph. D. Student 2 17%
Student > Bachelor 1 8%
Other 3 25%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 17%
Neuroscience 2 17%
Medicine and Dentistry 2 17%
Psychology 2 17%
Nursing and Health Professions 2 17%
Other 1 8%
Unknown 1 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2018.
All research outputs
#4,397,230
of 14,537,474 outputs
Outputs from Neuropsychiatric Disease and Treatment
#723
of 2,487 outputs
Outputs of similar age
#104,350
of 273,458 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#10
of 33 outputs
Altmetric has tracked 14,537,474 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,487 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,458 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.